scholarly journals In vitro Labeling of Human Embryonic Stem Cells for Magnetic Resonance Imaging

Author(s):  
Mayumi Yamada ◽  
Phillip Yang
2017 ◽  
Vol 30 (1) ◽  
pp. 71-79 ◽  
Author(s):  
Geeta Shroff

Introduction Spinal cord injury is a cause of severe disability and mortality. The pharmacological and non-pharmacological methods used, are unable to improve the quality of life in spinal cord injury. Spinal disorders have been treated with human embryonic stem cells. Magnetic resonance imaging and tractography were used as imaging modality to document the changes in the damaged cord, but the magnetic resonance imaging tractography was seen to be more sensitive in detecting the changes in the spinal cord. The present study was conducted to evaluate the diagnostic modality of magnetic resonance imaging tractography to determine the efficacy of human embryonic stem cells in chronic spinal cord injury. Materials and methods The study included the patients with spinal cord injury for whom magnetic resonance imaging tractography was performed before and after the therapy. Omniscan (gadodiamide) magnetic resonance imaging tractography was analyzed to assess the spinal defects and the improvement by human embryonic stem cell treatment. The patients were also scored by American Spinal Injury Association scale. Results Overall, 15 patients aged 15–44 years with clinical manifestations of spinal cord injury had magnetic resonance imaging tractography performed. The average treatment period was nine months. The majority of subjects ( n = 13) had American Spinal Injury Association score A, and two patients were at score C at the beginning of therapy. At the end of therapy, 10 patients were at score A, two patients were at score B and three patients were at score C. Improvements in patients were clearly understood through magnetic resonance imaging tractography as well as in clinical signs and symptoms. Conclusion Magnetic resonance imaging tractography can be a crucial diagnostic modality to assess the improvement in spinal cord injury patients.


2008 ◽  
Vol 136 (4) ◽  
pp. 1028-1037.e1 ◽  
Author(s):  
Stephen L. Hendry ◽  
Koen E.A. van der Bogt ◽  
Ahmad Y. Sheikh ◽  
Takayasu Arai ◽  
Scott J. Dylla ◽  
...  

NeuroImage ◽  
2005 ◽  
Vol 24 (3) ◽  
pp. 635-645 ◽  
Author(s):  
Albrecht Stroh ◽  
Cornelius Faber ◽  
Thomas Neuberger ◽  
Peer Lorenz ◽  
Katharina Sieland ◽  
...  

Stem Cells ◽  
2007 ◽  
Vol 25 (11) ◽  
pp. 2936-2944 ◽  
Author(s):  
Steven N. Ebert ◽  
David G. Taylor ◽  
Ha-Long Nguyen ◽  
David P. Kodack ◽  
Ronald J. Beyers ◽  
...  

Author(s):  
Eun-Young Shin ◽  
Seah Park ◽  
Won Yun Choi ◽  
Dong Ryul Lee

Abstract Background: Leydig cells (LCs) are testicular somatic cells that are the major producers of testosterone in males. Testosterone is essential for male physiology and reproduction. Reduced testosterone levels lead to hypogonadism and are associated with diverse pathologies, such as neuronal dysfunction, cardiovascular disease, and metabolic syndrome. LC transplantation is a promising therapy for hypogonadism; however, the number of LCs in the testis is very rare and they do not proliferate in vitro. Therefore, there is a need for an alternative source of LCs. Methods: To develop a safer, simple, and rapid strategy to generate human LC-like cells (LLCs) from stem cells, we first performed preliminary tests under different conditions for the induction of LLCs from human CD34/CD73 double positive-testis-derived stem cells (HTSCs). Based on the embryological sequence of events, we suggested a 3-step strategy for the differentiation of human ESCs into LLCs. We generated the mesendoderm in the first stage and intermediate mesoderm (IM) in the second stage and optimized the conditions for differentiation of IM into LLCs by comparing the secreted testosterone levels of each group. Results: HTSCs and human embryonic stem cells can be directly differentiated into LLCs by defined molecular compounds within a short period. Human ESC-derived LLCs can secrete testosterone and express steroidogenic markers. Conclusion: We developed a rapid and efficient protocol for the production of LLCs from stem cells using defined molecular compounds. These findings provide a new therapeutic cell source for male hypogonadism.


2013 ◽  
Vol 14 (12) ◽  
pp. 4207-4216 ◽  
Author(s):  
Matthew Leung ◽  
Ashleigh Cooper ◽  
Soumen Jana ◽  
Ching-Ting Tsao ◽  
Timothy A. Petrie ◽  
...  

2010 ◽  
Vol 6 (2) ◽  
pp. 237-247 ◽  
Author(s):  
Elaine Vo ◽  
Donny Hanjaya-Putra ◽  
Yuanting Zha ◽  
Sravanti Kusuma ◽  
Sharon Gerecht

Sign in / Sign up

Export Citation Format

Share Document